Preventing Progression: A Comprehensive Approach to Managing Parkinson's Disease
DOI:
https://doi.org/10.12775/QS.2024.15.52254Keywords
Parkinson’s Disease, physical activity, Mediterranean diet, PD, Ketogenic diet, cognitive stimulation, levodopa, Parkinson’s disease treatment, PD treatmentAbstract
Parkinson’s disease (PD) is the second-most common neurodegenerative disease and the most common synucleinopathy. It is a multi-system disease with both motor and non-motor disorders, cause of suffering for patients and a burden for healthcare system. Due to the constantly increasing number of patients and still unknown disease-modifying treatment, it is necessary to look for an effective way to slow down the progression. The article explores factors influencing PD progression, focusing on physical activity, nutrition, cognitive stimulation, and medical management. It underscores the need for a multidimensional approach to address the complex nature of PD and offers insights into potential strategies for slowing down Parkinson’s disease progression.
References
Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36[1]:1-12. doi:10.1016/j.cger.2019.08.002
Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19[2]:170-178. doi:10.1016/S1474-4422[19]30287-X
Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22[11]:657-673. doi:10.1038/s41577-022-00684-6
https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
Dorsey ER, Bloem BR. The Parkinson Pandemic—A Call to Action. JAMA Neurol. 2018;75[1]:9–10. doi:10.1001/jamaneurol.2017.3299
Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8[s1]:S3-S8. doi:10.3233/JPD-181474
Goldman SM, Marek K, Ottman R, et al. Concordance for Parkinson's disease in twins: A 20-year update. Ann Neurol. 2019;85[4]:600-605. doi:10.1002/ana.25441
Dams J, Zapp JJ, König HH. Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: An Updated Methodological Review. Pharmacoeconomics. 2023;41[10]:1205-1228. doi:10.1007/s40273-023-01289-0
Liu, W.-Y., Tung, T.-H., Zhang, C., & Shi, L. [2022]. Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease. Brain and Behavior, 12, e2690. https://doi.org/10.1002/brb3.2690
Johansson ME, Cameron IGM, Van der Kolk NM, et al. Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial. Ann Neurol. 2022;91[2]:203-216. doi:10.1002/ana.26291
Ellis TD, Colón-Semenza C, DeAngelis TR, et al. Evidence for Early and Regular Physical Therapy and Exercise in Parkinson's Disease. Semin Neurol. 2021;41[2]:189-205. doi:10.1055/s-0041-1725133
Yuan RY, Chen SC, Peng CW, Lin YN, Chang YT, Lai CH. Effects of interactive video-game-based exercise on balance in older adults with mild-to-moderate Parkinson's disease. J Neuroeng Rehabil. 2020;17[1]:91. Published 2020 Jul 13. doi:10.1186/s12984-020-00725-y
Cugusi L, Manca A, Bergamin M, et al. Aquatic exercise improves motor impairments in people with Parkinson's disease, with similar or greater benefits than land-based exercise: a systematic review. J Physiother. 2019;65[2]:65-74. doi:10.1016/j.jphys.2019.02.003
Włodarek D. Role of Ketogenic Diets in Neurodegenerative Diseases [Alzheimer’s Disease and Parkinson’s Disease]. Nutrients. 2019; 11[1]:169. https://doi.org/10.3390/nu11010169
Bisaglia M. Mediterranean Diet and Parkinson's Disease. Int J Mol Sci. 2022;24[1]:42. Published 2022 Dec 20. doi:10.3390/ijms24010042
Mischley LK, Lau RC, Bennett RD. Role of Diet and Nutritional Supplements in Parkinson's Disease Progression. Oxid Med Cell Longev. 2017;2017:6405278. doi:10.1155/2017/6405278
Park, M., Ross, G. W., Petrovitch, H., White, L. R., Masaki, K. H., Nelson, J. S., et al. [2005]. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64, 1047–1051. doi: 10.1212/01.WNL.0000154532.98495.BF
Chen H, O’Reilly E, McCullough ML, et al. Consumption of Dairy Products and Risk of Parkinson’s Disease. American Journal of Epidemiology. 2007;165[9]:998-1006. doi:https://doi.org/10.1093/aje/kwk089
Tucker LA, Erickson A, LeCheminant JD, Bailey BW. Dairy consumption and insulin resistance: the role of body fat, physical activity, and energy intake. J Diabetes Res. 2015;2015:206959. doi:10.1155/2015/206959
Shaltiel-Karyo R, Frenkel-Pinter M, Rockenstein E, et al. A Blood-Brain Barrier [BBB] Disrupter Is Also a Potent α-Synuclein [α-syn] Aggregation Inhibitor. Journal of Biological Chemistry. 2013;288[24]:17579-17588. doi:https://doi.org/10.1074/jbc.m112.434787
Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22[2]:79-94. doi:https://doi.org/10.1007/s10787-013-0191-7
Zhou Z, Zhou R, Zhang Z, Li K. The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis. Med Sci Monit. 2019;25:666-674. Published 2019 Jan 23. doi:10.12659/MSM.912840
Wang W, Li Y, Meng X. Vitamin D and neurodegenerative diseases. Heliyon. 2023;9(1):e12877. Published 2023 Jan 12. doi:10.1016/j.heliyon.2023.e12877
Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011;26[10]:1814-1824. doi:10.1002/mds.23823
Lawrence BJ, Gasson N, Loftus AM. Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson's Disease. Sci Rep. 2016;6:33929. Published 2016 Sep 21. doi:10.1038/srep33929
Sun C, Armstrong MJ. Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions. Behav Sci [Basel]. 2021;11[4]:54. Published 2021 Apr 17. doi:10.3390/bs11040054
Del Felice A, Castiglia L, Formaggio E, et al. Personalized transcranial alternating current stimulation [tACS] and physical therapy to treat motor and cognitive symptoms in Parkinson's disease: A randomized cross-over trial. Neuroimage Clin. 2019;22:101768. doi:10.1016/j.nicl.2019.101768
Zhang Q, Aldridge GM, Narayanan NS, Anderson SW, Uc EY. Approach to Cognitive Impairment in Parkinson's Disease. Neurotherapeutics. 2020;17[4]:1495-1510. doi:10.1007/s13311-020-00963-x
Aradi SD, Hauser RA. Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics. 2020;17[4]:1339-1365. doi:10.1007/s13311-020-00889-4
Woitalla D, Buhmann C, Hilker-Roggendorf R, et al. Role of dopamine agonists in Parkinson's disease therapy [published correction appears in J Neural Transm [Vienna]. 2023 Sep 13;:]. J Neural Transm [Vienna]. 2023;130[6]:863-873. doi:10.1007/s00702-023-02647-0
Fabbri M, Ferreira JJ, Rascol O. COMT Inhibitors in the Management of Parkinson's Disease. CNS Drugs. 2022;36[3]:261-282. doi:10.1007/s40263-021-00888-9
Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J Parkinsons Dis. 2022;12[2]:477-493. doi:10.3233/JPD-212976
Isaacson SH, Betté S, Pahwa R. Istradefylline for OFF Episodes in Parkinson's Disease: A US Perspective of Common Clinical Scenarios. Degener Neurol Neuromuscul Dis. 2022;12:97-109. Published 2022 Jul 23. doi:10.2147/DNND.S245197
Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 2021;20[12]:1048-1056. doi:10.1016/S1474-4422[21]00249-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Barbara Borodziuk, Filip Borodziuk, Katarzyna Ciuba, Paulina Dąbrowska, Michał Żuber, Karol Bochyński, Katarzyna Molenda, Michał Dacka, Kamila Giżewska, Konrad Białogłowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 93
Number of citations: 0
